Immuron Ltd ANW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.05
- Day Range
- A$0.05–0.05
- 52-Week Range
- A$0.03–0.49
- Bid/Ask
- A$0.00 / A$0.00
- Market Cap
- A$12.30 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6
- Website
- https://www.immuron.com.au
Valuation
|
Metric
|
ANW
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.14 |
Price/Sales | 5.61 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANW
|
|---|---|
Quick Ratio | 7.63 |
Current Ratio | 8.52 |
Interest Coverage | −446.38 |
Quick Ratio
ANW
Profitability
|
Metric
|
ANW
|
|---|---|
Return on Assets (Normalized) | −13.08% |
Return on Equity (Normalized) | −14.55% |
Return on Invested Capital (Normalized) | −15.52% |
Return on Assets
ANW
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Rxbwggcm | Nrdrcg | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nbxcfvjph | Jzlcf | $114.2 Bil | |||
| Moderna Inc
MRNA
| Chwypnx | Ldqd | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Rcsnxbyr | Vyysh | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Zpdxxcl | Fjhq | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lvxxmdz | Kqxvjm | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sqxjdgcm | Gtgmpx | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Qdcxnvsq | Hqjb | $12.8 Bil | |||
| Incyte Corp
INCY
| Wrxgdshfk | Pzxjcd | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ysyytxwy | Jbwlgnd | $12.2 Bil |